Skip to main content
. Author manuscript; available in PMC: 2017 Nov 15.
Published in final edited form as: Cancer Res. 2016 Sep 15;76(22):6723–6734. doi: 10.1158/0008-5472.CAN-15-3327

Figure 5. Cyclin D1 is required for v-Src induced Trop2 ICD.

Figure 5

(A) -3,400bp cyclin D1-Luc activity was induced ~2-fold by v-Src in 293T cells, and (B) reduced 80% by Dasatinib in v-Src PEC cells. (C) The nuclear abundance of the Trop2 ICD is reduced in the cyclin D1-/- prostate epithelium compared to cyclin D1+/+. (D) Cyclin D1 shRNA induced by doxycycline in LNCaP cell with (E) Western blot analysis demonstrating the reduction in cyclin D1 abundance associated with a decrease in the Trop2 ICD. Vinculin is a protein loading control. (F-G) In cyclin D1 shRNA-treated LNCaP cells, the Trop2 ICD was reduced, shown by immunofluorescence staining (H) The Src Kinase inhibitors Dasatinib and PP1 reduced CBF activity in a dose-dependent manner in v-Src PEC. (I) CBF-Luc activity activity is shown in cyclin D1 siRNA-treated v-Src PEC cells.